Your browser doesn't support javascript.
loading
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
O'Brien, Meagan P; Forleo-Neto, Eduardo; Sarkar, Neena; Isa, Flonza; Hou, Peijie; Chan, Kuo-Chen; Musser, Bret J; Bar, Katharine J; Barnabas, Ruanne V; Barouch, Dan H; Cohen, Myron S; Hurt, Christopher B; Burwen, Dale R; Marovich, Mary A; Brown, Elizabeth R; Heirman, Ingeborg; Davis, John D; Turner, Kenneth C; Ramesh, Divya; Mahmood, Adnan; Hooper, Andrea T; Hamilton, Jennifer D; Kim, Yunji; Purcell, Lisa A; Baum, Alina; Kyratsous, Christos A; Krainson, James; Perez-Perez, Richard; Mohseni, Rizwana; Kowal, Bari; DiCioccio, A Thomas; Geba, Gregory P; Stahl, Neil; Lipsich, Leah; Braunstein, Ned; Herman, Gary; Yancopoulos, George D; Weinreich, David M.
Afiliación
  • O'Brien MP; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Forleo-Neto E; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Sarkar N; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Isa F; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Hou P; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Chan KC; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Musser BJ; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Bar KJ; Department of Medicine, University of Pennsylvania, Philadelphia.
  • Barnabas RV; Department of Microbiology, University of Pennsylvania, Philadelphia.
  • Barouch DH; Department of Global Health, University of Washington, Seattle.
  • Cohen MS; Division of Allergy and Infectious Diseases, University of Washington, Seattle.
  • Hurt CB; Department of Epidemiology, University of Washington, Seattle.
  • Burwen DR; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Marovich MA; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Brown ER; Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill.
  • Heirman I; Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill.
  • Davis JD; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland.
  • Turner KC; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland.
  • Ramesh D; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Mahmood A; Department of Biostatistics, University of Washington, Seattle.
  • Hooper AT; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Hamilton JD; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Kim Y; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Purcell LA; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Baum A; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Kyratsous CA; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Krainson J; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Perez-Perez R; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Mohseni R; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Kowal B; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • DiCioccio AT; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Geba GP; Clinical Trials of Florida LLC, Miami.
  • Stahl N; Medical Research of Westchester, Miami, Florida.
  • Lipsich L; Catalina Research Institute LLC, Montclair, California.
  • Braunstein N; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Herman G; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Yancopoulos GD; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
  • Weinreich DM; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
JAMA ; 327(5): 432-441, 2022 02 01.
Article en En | MEDLINE | ID: mdl-35029629
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / SARS-CoV-2 / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Año: 2022 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / SARS-CoV-2 / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Año: 2022 Tipo del documento: Article